Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Ortho Panel Will See Second Hip Resurfacing System In Cormet

This article was originally published in The Gray Sheet

Executive Summary

Corin Group's Cormet will be the second hip resurfacing product to go before an FDA advisory committee when the Orthopaedic and Rehabilitation panel considers the device's PMA next month

You may also be interested in...



Hip Resurfacing Technology Aids S&N Stock Gain In Q1 - Index Up 1.1%

Investor enthusiasm for hip resurfacing's market potential was among factors contributing to Smith & Nephew's 21.3% stock price gain in the first quarter

Hip Resurfacing Technology Aids S&N Stock Gain In Q1 - Index Up 1.1%

Investor enthusiasm for hip resurfacing's market potential was among factors contributing to Smith & Nephew's 21.3% stock price gain in the first quarter

Corin’s Cormet 2000 Hip Resurfacing System Is “Approvable With Conditions”

Corin's Cormet 2000 hip resurfacing system requires a postmarket study to address long-term safety concerns, FDA's Orthopedic and Rehabilitation Devices Panel recommended Feb. 22

Related Content

UsernamePublicRestriction

Register

LL016481

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel